Patents by Inventor Andrew Pennell
Andrew Pennell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090270616Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: CHEMOCENTRYX, INCInventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
-
Patent number: 7582661Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: GrantFiled: January 27, 2005Date of Patent: September 1, 2009Assignee: ChemoCentryx, Inc.Inventors: Solomon Ugashe, Zheng Wei, John J. Wright, Andrew Pennell
-
Publication number: 20090163498Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: June 11, 2008Publication date: June 25, 2009Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
-
Publication number: 20090118307Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: October 15, 2008Publication date: May 7, 2009Applicant: CHEMOCENTRYX, INC.Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20080293717Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 2, 2008Publication date: November 27, 2008Applicant: CHEMOCENTRYX, INC.Inventors: SOLOMON UGASHE, Zheng Wei, J.J. Wright, Andrew Pennell
-
Publication number: 20080261966Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: February 1, 2008Publication date: October 23, 2008Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7420055Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: GrantFiled: May 13, 2004Date of Patent: September 2, 2008Assignee: Chemocentryx, Inc.Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
-
Publication number: 20080161345Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.Type: ApplicationFiled: May 12, 2005Publication date: July 3, 2008Inventors: Solomon Ungashe, John Jessen Wright, Andrew Pennell
-
Publication number: 20080058341Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: May 22, 2007Publication date: March 6, 2008Inventors: Penglie Zhang, Andrew Pennell, John Wright, Wei Chen, Manmohan Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark Gleason, Yibin Zeng, Kevin Greenman
-
Patent number: 7335653Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: GrantFiled: April 23, 2007Date of Patent: February 26, 2008Assignee: ChemoCentryx, Inc.Inventors: Solomon Ungashe, Zheng Wei, John J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Publication number: 20080039465Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 10, 2007Publication date: February 14, 2008Inventors: Trevor Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew Pennell, Sreenivas Punna, Edward Sullivan, Xuefei Tan, William Thomas, Solomon Ungashe, Yibin Zeng
-
Publication number: 20080039504Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 10, 2007Publication date: February 14, 2008Inventors: Trevor Charvat, Cheng Hu, Jeff Jin, Yandong Li, Anita Melikian, Andrew Pennell, Sreenivas Punna, Solomon Ungashe, Yibin Zeng
-
Publication number: 20070275965Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.Type: ApplicationFiled: March 30, 2007Publication date: November 29, 2007Applicant: ChemoCentryx, Inc.Inventors: William Thomas, Manmohan Leleti, Andrew Pennell
-
Publication number: 20070254915Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.Type: ApplicationFiled: March 30, 2007Publication date: November 1, 2007Applicant: ChemoCentryx, Inc.Inventors: Manmohan Leleti, William Thomas, Penglie Zhang, Andrew Pennell
-
Publication number: 20070203131Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: ApplicationFiled: April 23, 2007Publication date: August 30, 2007Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 7227035Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: GrantFiled: May 19, 2004Date of Patent: June 5, 2007Assignee: ChemocentryxInventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Publication number: 20070112015Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.Type: ApplicationFiled: October 30, 2006Publication date: May 17, 2007Applicant: ChemoCentryx, Inc.Inventors: Clarence Hurt, Andrew Pennell, John Wright, Manmohan Leleti, Qiang Wang, William Thomas, Yandong Li, Dean Dragoli
-
Publication number: 20070093467Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: October 11, 2006Publication date: April 26, 2007Applicant: ChemoCentryx, Inc.Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Edward Sullivan, Lianfa Li
-
Publication number: 20070088036Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: October 11, 2006Publication date: April 19, 2007Applicant: ChemoCentryx, Inc.Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Lianfa Li, Edward Sullivan
-
Publication number: 20070066583Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: August 14, 2006Publication date: March 22, 2007Applicant: ChemoCentryx, Inc.Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Lianfa Li, Edward Sullivan, Wei Chen, Kevin Lloyd Greenman
